Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 3/20 | 0.49 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.39 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.38 |
| ▸ | OPRL1 | P41146 | 2/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | ACHE | P22303 | 1/20 | 0.37 |
| ▸ | USP2 | O75604 | 1/20 | 0.37 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.36 |
| ▸ | UTS2R | Q9UKP6 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4697427 | 1.00 | HSD11B1 (0.49) | HSD11B1HRH3OPRM1OPRL1POLB | |
| SCHEMBL4696982 | 1.00 | HSD11B1 (0.49) | HSD11B1HRH3OPRM1OPRL1POLB | |
| SCHEMBL4697081 | 0.93 | HSD11B1 (0.54) | HSD11B1OPRM1OPRL1ACHESIGMAR1 | |
| SCHEMBL4698786 | 0.93 | HSD11B1 (0.54) | HSD11B1OPRM1OPRL1ACHESIGMAR1 | |
| SCHEMBL4699865 | 0.89 | HSD11B1 (0.62) | HSD11B1HRH3OPRM1OPRL1POLB | |
| SCHEMBL4697328 | 0.88 | HSD11B1 (0.40) | HSD11B1 | |
| SCHEMBL4696931 | 0.88 | HSD11B1 (0.40) | HSD11B1 | |
| SCHEMBL4700723 | 0.88 | HSD11B1 (0.41) | HSD11B1 | |
| SCHEMBL4696680 | 0.88 | HSD11B1 (0.41) | HSD11B1 | |
| SCHEMBL4701305 | 0.88 | HSD11B1 (0.41) | HSD11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080214621-A1 | Cycloalkyl Lactam Derivatives As Inhibitors Of 11-Beta-Hydroxysteroid Dehydrogenase 1 | ELI LILLY AND COMPANY | 2008-09-04 | — | — | US | claimed |
| EP-1830841-B1 | CYCLOALKYL LACTAM DERIVATIVES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1 | LILLY CO ELI (US) | 2008-07-02 | — | — | EP | claimed |
| EP-1830841-B1 | CYCLOALKYL LACTAM DERIVATIVES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1 | LILLY CO ELI (US) | 2008-07-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080214621-A1 | Cycloalkyl Lactam Derivatives As Inhibitors Of 11-Beta-Hydroxysteroid Dehydrogenase 1 | HSD11B1, HSD17B1, HSD3B1 | HSD11B1 1/4885HRH3 977/4885OPRM1 2031/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.